Connect with us

News

JenaValve Technology Strengthens Senior Leadership Team in Clinical Affairs and Operations

gbafNews28

JenaValve Technology, Inc., a developer of a novel transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, today announced the appointment of two veteran medical device executives Vinny Podichetty, MD, MS as Vice President, Clinical Affairs, and Jeff Thiel as Vice President, Operations, effective immediately.

Dr. Podichetty is an accomplished medical device executive with approximately 20 years of clinical, medical and regulatory affairs experience. He has developed and managed successful multinational, high-profile clinical projects and regulatory plans in both startup and large company environments. He last served as Vice President, Global Clinical & Regulatory Affairs at IRRAS, a global medical technology company based in San Diego, and previously held senior clinical affairs positions at Edwards Lifesciences, MicroVention and Zimmer Biomet. His experience includes work in structural heart, interventional neuroradiology and orthopedics. Dr. Podichetty earned a Doctor of Medicine at MH Institute of Medical Sciences & Research and a Master of Science from Cleveland State University.

Mr. Thiel has more than 30 years of operations and executive leadership experience in medical devices, primarily with venture-backed emerging growth medical device companies. He last served as President and CEO of Devax, Inc., a drug eluting stent company which obtained CE Mark and U.S. investigational device exemption (IDE) approval for its Axxess bifurcation stent. He previously served as President and CEO of Radiance Medical Systems, where he initially served as Vice President of Operations. He started his medical device career with St. Jude Medical where he successfully transferred the companys mechanical valve production from St. Paul, Minnesota to Puerto Rico. He also served as a member of the Board of Directors of Micrus Endovascular, helping to drive it from a venture-backed start-up to a public company and its subsequent sale to Johnson & Johnson. Mr. Thiel holds an MBA from the College of St. Thomas and a BS in Economics from the University of Wisconsin-River Falls.

As we look forward to accelerating our clinical and commercial development plans, I am pleased to have this caliber of management experience bolster our senior leadership team. Both Vinny and Jeff bring established track records in building and executing the growth strategies of emerging medical technologies, said John Kilcoyne, Chief Executive Officer. I look forward to their contributions to managing our collective efforts and driving our breakthrough TAVR technology to meet the significant unmet needs of patients who suffer from severe aortic regurgitation as well as aortic stenosis.

About JenaValve

JenaValve, with locations in Irvine, California, Leeds, U.K, and Munich, Germany, is focused on bringing to market the JenaValve Transfemoral TAVR System which consists of a transcatheter heart valve (THV) and a transfemoral delivery system. The bioprosthesis comprises a self-expanding nitinol stent with a porcine pericardial valve manufactured using state-of-the-art tissue processing techniques. The transfemoral delivery catheter is designed to deliver the bioprosthesis using a simple stepped approach resulting in anatomical alignment with the native valves. The System is available in three sizes intended for aortic annulus diameters from 21mm to 27mm. JenaValve is backed by investors, including Andera Partners (formerly Edmond de Rothschild Investment Partners), Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. Additional information is available at www.jenavalve.com.

The JenaValve Transfemoral TAVR System is an investigational device in the United States and internationally.

Investor and Media Contact:

Matt Clawson

W2Opure

(949) 370-8500

[email protected]

News

Plymouth Industrial REIT Declares Fourth Quarter 2020 Preferred Stock Dividend

gbafNews28

Plymouth Industrial REIT, Inc. (NYSE: PLYM) today announced that the Companys board of directors declared a regular quarterly cash dividend of $0.46875 per share, or an annualized dividend of $1.875 per share, for the Companys 7.50% Series A Cumulative Redeemable Preferred Stock (PLYM-PrA) for the fourth quarter of 2020. The dividend is payable on December 31, 2020, to stockholders of record on December 15, 2020.

About Plymouth

Plymouth Industrial REIT, Inc. is a vertically integrated and self-managed real estate investment trust focused on the acquisition and operation of single and multi-tenant industrial properties located in secondary and select primary markets across the United States. The Company seeks to acquire properties that provide income and growth that enable the Company to leverage its real estate operating expertise to enhance shareholder value through active asset management, prudent property re-positioning and disciplined capital deployment.

Tripp Sullivan

SCR Partners

(615) 942-7077

[email protected]

Continue Reading

News

Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook

gbafNews28

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy products, which are used to treat patients of all ages suffering from respiratory distress, today announced an update to its fourth quarter and fiscal year 2020 revenue guidance given on November 4, 2020.

Fourth Quarter and Fiscal Year 2020 Outlook

For fourth quarter 2020, we now expect revenue in the range of $30.0 million to $33.0 million, which reflects an increase of $12.0 million to $13.0 million over our previously announced revenue guidance of $18.0 million to $20.0 million. This new revenue guidance implies fiscal year revenue in the range of $114.8 million to $117.8 million, an increase from our previously announced revenue guidance of $102.8 million to $104.8 million.

The global impact of COVID has materially accelerated since we provided our fourth quarter and fiscal year 2020 revenue guidance in early November. We have seen higher capital demand worldwide and higher disposable demand in the US related to increased hospitalization rates, said Joe Army, President and CEO of Vapotherm. Wed like to thank all healthcare professionals around the world for their efforts, and our teammates and partners for supporting them during this pandemic.

About Vapotherm

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 2.5 million patients have been treated with the use of Vapotherm high velocity therapy systems. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow systems mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Website Information

Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherms disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherms website, in addition to following Vapotherms press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherms website is not incorporated by reference into, and is not a part of, this document.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements about expected revenue for the fourth quarter and fiscal year 2020. In some cases, you can identify forward-looking statements by terms such as ˜˜expect, guide or typically or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future, Vapotherm may need to raise additional capital to fund its existing commercial operations, develop and commercialize new products, and expand its operations, Vapotherms dependence on sales generated from its Precision Flow systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market, the ability for Precision Flow systems to gain increased market acceptance, its inexperience directly marketing and selling its products, the potential loss of one or more suppliers, Vapotherms susceptibility to seasonal fluctuations, Vapotherms failure to comply with applicable United States and foreign regulatory requirements, the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain, or enforce patent or other intellectual property protection for its products, the impact of the COVID-19 pandemic on its business, including its supply chain, and the other risks and uncertainties included under the heading Risk Factors in Vapotherms Annual Report on Form 10-K for the fiscal year ended December, 31, 2019, as filed with the SEC on March 4, 2020, Vapotherms Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as filed with the SEC on May 5, 2020, Vapotherms Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as filed with the SEC on August 4, 2020, and Vapotherms Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as filed with the SEC on November 4, 2020 and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Vapotherms views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contacts:

Mark Klausner or Mike Vallie, Westwicke, an ICR Company, [email protected], +1 (603) 658-0011

Continue Reading

News

Twist Bioscience Announces Proposed Public Offering of Common Stock

gbafNews28

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it intends to offer and sell in an underwritten public offering up to $250 million of shares of its common stock and certain selling stockholders intend to offer 75,000 shares in the offering. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to $37.5 million of shares of its common stock offered by it in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Twist will not receive any proceeds from the sale of shares in the offering by the selling stockholders.

Twist intends to use the net proceeds of the shares offered by it, along with its existing cash, cash equivalents and short-term investments to increase its operational capacity, tooling, and scaling an additional manufacturing location to support its growth in NGS, synbio, DNA prep, its pharmaceutical biologics antibody platform and IGG products; increase its investment in automation and research and development, which includes investing in NGS, synbio, its pharmaceutical biologics antibody platform, and in DNA data storage; increase its investment in its commercial organization and its IT infrastructure; and for the remainder to fund working capital and general corporate purposes. Twist may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers. Robert W. Baird & Co. Incorporated is acting as lead manager.

The securities described above are being offered by Twist and the selling stockholders pursuant to an automatic shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (the SEC) on June 3, 2020. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SECs website. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by request from J.P. Morgan Securities LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at [email protected], or from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department, by telephone at (866) 471-2526, or by email at [email protected], or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at [email protected] or by telephone at (833) 297-2926, or from Evercore Group L.L.C. c/o Equity Capital Markets, 55 East 52nd Street, 35thFloor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation statements regarding the offer and sale of shares, the terms of the offering and expected use of proceeds to be received by it in the offering are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Biosciences actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties set forth in Twist Biosciences Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 27, 2020, the preliminary prospectus supplement related to the proposed public offering and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Twist Biosciences results of operations, which would, in turn, have a significant and adverse impact on Twist Biosciences stock price. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:

Angela Bitting

925-202-6211

[email protected]

Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News34 mins ago

Twist Bioscience Announces Proposed Public Offering of Common Stock

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its...

gbafNews28 gbafNews28
News34 mins ago

Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook

Vapotherm, Inc. (NYSE: VAPO), (Vapotherm or the Company), a global medical technology company focused on the development and commercialization of...

gbafNews28 gbafNews28
News34 mins ago

Plymouth Industrial REIT Declares Fourth Quarter 2020 Preferred Stock Dividend

Plymouth Industrial REIT, Inc. (NYSE: PLYM) today announced that the Companys board of directors declared a regular quarterly cash dividend...

gbafNews28 gbafNews28
News35 mins ago

Whatfix Partners with Local Australian Government Councils To Help Employees Embrace Digital Platforms

Whatfix, the leader in Digital Adoption Solutions (DAS), today announced strategic partnerships with Australian local government, the Moorabool Shire, the...

gbafNews28 gbafNews28
News35 mins ago

XAI Octagon Floating Rate & Alternative Income Term Trust Declares its Monthly Distribution of $0.073 per Share

XAI Octagon Floating Rate & Alternative Income Term Trust (XFLT or the Trust) has declared its regular monthly distribution of...

gbafNews28 gbafNews28
News35 mins ago

Fifth Third Bancorp to Attend Goldman Sachs U.S. Financial Services Conference

Fifth Third Bancorp (Nasdaq: FITB) will attend the 2020 Goldman Sachs U.S. Financial Services Conference on December 8, 2020 at...

gbafNews28 gbafNews28
News35 mins ago

Cirrus Logic to Present at Barclays Global Technology, Media and Telecommunications Conference

Cirrus Logic, Inc. (Nasdaq: CRUS) today announced that President John Forsyth will present at the Barclays Global Technology, Media and...

gbafNews28 gbafNews28
News35 mins ago

Uber CFO to Participate in Fireside Chat at 2020 Barclays Global Technology, Media and Telecommunications Conference

Uber Technologies, Inc. (NYSE: UBER) announced today that Nelson Chai, CFO, will participate in a fireside chat at the 2020...

gbafNews28 gbafNews28
News36 mins ago

Organic Garage Unaware of Any Material Change

At the request of IIROC, Organic Garage Ltd. (Organic Garage or the Company) (TSXV:OG), one of Canadas leading independent grocery...

gbafNews28 gbafNews28
News49 mins ago

ESPN Broadcaster Sarah Spain Joins Impact Podcast’s Stellar December Guestlist

A lineup of experts and impactful thought leaders, including espnW.com columnist, ESPN Radio host, ESPN television personality and occasional SportsCenter...